VNRX Stock Overview
A multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VolitionRx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$1.23 |
| 52 Week Low | US$0.43 |
| Beta | 1.1 |
| 11 Month Change | 10.81% |
| 3 Month Change | 32.77% |
| 1 Year Change | 11.04% |
| 33 Year Change | -78.11% |
| 5 Year Change | -84.83% |
| Change since IPO | -73.00% |
Recent News & Updates
Shareholder Returns
| VNRX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.0% | -0.4% | -1.0% |
| 1Y | 11.0% | 20.3% | 30.3% |
Return vs Industry: VNRX underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: VNRX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| VNRX volatility | |
|---|---|
| VNRX Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VNRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VNRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 101 | Cameron Reynolds | www.volition.com |
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu Q Vet, a cancer screening test for dogs and other animals; Nu
VolitionRx Limited Fundamentals Summary
| VNRX fundamental statistics | |
|---|---|
| Market cap | US$61.71m |
| Earnings (TTM) | -US$29.87m |
| Revenue (TTM) | US$1.29m |
58.0x
P/S Ratio-2.5x
P/E RatioIs VNRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNRX income statement (TTM) | |
|---|---|
| Revenue | US$1.29m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.29m |
| Other Expenses | US$31.16m |
| Earnings | -US$29.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,323.23% |
| Debt/Equity Ratio | -21.2% |
How did VNRX perform over the long term?
See historical performance and comparison